Immutep S.A.S.
16
1
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
4 terminated/withdrawn out of 16 trials
63.6%
-22.9% vs industry average
6%
1 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
Role: lead
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
Role: collaborator
A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers
Role: lead
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Role: lead
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Role: lead
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
Role: collaborator
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Role: lead
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial
Role: collaborator
A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel
Role: lead
IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Role: lead
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
Role: collaborator
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Role: collaborator
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Role: lead
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Role: lead
A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321
Role: lead
Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen
Role: lead
All 16 trials loaded